tonixpharma.com - TNXP Company profit before taxes, interest and amortization
Tonix Pharmaceuticals (TNXP) minimizes risks through a diversified development pipeline in the fields of infectious diseases and neuropathic pain. Current EBITDA levels clearly demonstrate the volatility of operating cash flows, where the current value is 0.00. Profit growth is based on preparations to launch fibromyalgia treatments to market. Massive demand potential in the US promises the company a rapid expansion of its customer base.
Tonix Pharmaceuticals Holding Corp. - analytical breakdowns and key metrics (TNXP)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Tonix Pharmaceuticals|TNXP - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Tonix Pharma|TNXP - Company Debts|Debts to Book Value Tonix Pharmaceuticals|TNXP - Company Long-Term Debt|Company Short-Term Indebtedness Tonix Pharmaceuticals|Interim Coverage Ratio tonixpharma.com
- earnings and market ratios statistics:
TNXP - Net Income|Net Profit Forecast Tonix Pharmaceuticals|TNXP - Price to Earnings Ratio|Future Price to Earnings Multiple tonixpharma.com|TNXP - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Tonix Pharmaceuticals|TNXP - Operating profit EBITDA|Earnings per share for the trailing year Tonix Pharmaceuticals|TNXP - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth tonixpharma.com|TNXP - Earnings per share growth in current year|Expected earnings per share trend next year Tonix Pharmaceuticals
- sales revenue and business income indicators:
Analysis of all company metrics:Tonix Pharmaceuticals
This indicator measures real cash flow from core operations, allowing for an assessment of the business's ability to generate cash excluding financial and tax factors. The EBITDA_Co valuation analysis reveals the resilience of Tonix Pharmaceuticals (TNXP) operational processes to external shocks, which is critical for a company with a volatile reputation and a dependence on clinical trial results amid frequent secondary offerings.
Competitors of Tonix Pharmaceuticals (TNXP)
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Galapagos - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization ANIP (ANI Pharmaceuticals Inc)|MNKD - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Amphastar Corp|Pacira BioSciences (PCRX) - Profit before payment of interest, taxes and amortization|Operating profit before amortization SPRY|TBPH (Theravance Biopharma, Inc.) - Operating profit EBITDA|Aquestive Therapeutics Inc (AQST) - Operating income before deduction of amortization|Operating profit before deduction of amortization SCPH (scPharmaceuticals Inc.)|tectonictx.com - Operating profit before amortization|China SXT Pharmaceuticals, Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization EPRX|BHST - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization EXOZ|ORMP: Operating profit EBITDA|Entera Bio - Income before deduction of interest, taxes and amortization|HYFT (MindWalk Holdings) - Operating profit EBITDA|Operating profit EBITDA abvcpharma.com|Profit before payment of interest, taxes and amortization Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization FibroGen Corp FGEN|TELO - Operating profit before deduction of amortization|Rani Therapeutics Inc - Operating profit EBITDA|SNYR - Operating profit EBITDA|RLYB: Operating profit EBITDA|Operating profit before deduction of amortization Lexaria Bioscience Corp.|PULM (Pulmatrix Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization Pheton PTHL|Operating profit before deduction of amortization APM (Aptorum Group Limited)|Operating profit EBITDA lyratherapeutics.com (LYRA)|Impact BioMedical - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization TNFA (TNF Pharmaceuticals Inc.)|cbdMD Corp - Operating profit EBITDA|Operating income before deduction of amortization PainReform Corp PRFX|CYTO: Operating profit EBITDA|Operating profit before deduction of amortization lipella.com|OPTN (OptiNose) - Operating profit EBITDA|Operating profit EBITDA Pieris Pharmaceuticals Inc|Profit before payment of interest, taxes and amortization Procaps Group SA (PROC)|Profit before payment of interest, taxes and amortization PTPI (Petros Pharma)|Profit before payment of interest, taxes and amortization Qilian International QLI|Operating income before deduction of amortization acelyrin.com (SLRN)|TFFP: Operating profit before deduction of amortization
